Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Declines By 25.0%

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 220,000 shares, a decrease of 25.0% from the January 15th total of 293,400 shares. Based on an average daily trading volume, of 197,200 shares, the short-interest ratio is presently 1.1 days. Approximately 2.0% of the company’s shares are short sold.

ABVC BioPharma Stock Performance

ABVC opened at $0.46 on Friday. The company has a fifty day moving average price of $0.52 and a two-hundred day moving average price of $0.59. The firm has a market capitalization of $5.92 million, a PE ratio of -0.53 and a beta of 0.67. ABVC BioPharma has a 52 week low of $0.40 and a 52 week high of $1.73.

Institutional Investors Weigh In On ABVC BioPharma

A hedge fund recently raised its stake in ABVC BioPharma stock. Avantax Planning Partners Inc. raised its stake in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) by 269.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 143,968 shares of the company’s stock after buying an additional 104,968 shares during the quarter. Avantax Planning Partners Inc. owned about 1.11% of ABVC BioPharma worth $85,000 at the end of the most recent reporting period. 11.38% of the stock is currently owned by institutional investors.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.